Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idasanutlin in Hydroxyurea-Resistant/Intolerant Polycythemia Vera
NCT03287245Phase 2Terminated
- Sponsor
- Roche
- Start
- Feb 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of idasanutlin in polycythemia vera (PV), sponsored by Roche. Started Feb 2018; status: terminated.
02
Drugs
idasanutlin
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT03287245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287245.